Autoimmune Diseases
Francis N, Arends S, Choi JC, Becker B, Edwards T, Sreih A, Christodoulou A, Strand V. Qualitative study on patient-reported outcome measures in patients with Sjögren's disease. Poster presented at the Congress of Clinical Rheumatology - East 2025; May 1, 2025. Destin, FL.
Riemer J, Campbell K, Arthurs E, Knight C. Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
OBJECTIVES: To evaluate the costs and health outcomes of belimumab plus standard therapy (ST) versus ST alone for the treatment of adults with active lupus nephritis (LN) in Canada from a healthcare payer perspective.
Layton JB, Anderson-Smits C, Huang Z, Ay H, Spalding W, Khokhar B, Zhou J, Bennett L, Anthony MS. A comparative real-world study evaluating the safety of immune globulin infusion (human) 10% solution and other intravenous immunoglobulin therapies for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Pharmacoepidemiol Drug Saf. 2025 Mar;34(3):e70124. doi: 10.1002/pds.70124
Law EH, Hanson KA, Harries M, Korver D, Sherif B, Chirila C. Patient-reported outcome improvements following scalp hair regrowth among patients with alopecia areata: analysis of the ALLEGRO-2b/3 trial. J Dermatolog Trea. 2025 Feb 3;36(1):2460577. doi: 10.1080/09546634.2025.2460577
PURPOSE: Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life of people living with AA. Clinically meaningful hair regrowth is possible, but the relationship with downstream patient-reported outcomes (PROs) is complex.
Wright GC, Zueger PM, Copley-Merriman K, Khan S, Costello J, Krumbach A, Reddy P, Tanjinatus O, Wells AF. Health disparities in rheumatology in the United States. Open Access Rheumatol. 2025 Jan 9;17:1-12. doi: 10.2147/OARRR.S493457
OBJECTIVE: Underserved populations are often at risk of experiencing systematic healthcare disparities. Existing disparities in care access, quality of care received, and treatment outcomes among patients with rheumatic disease are not well understood.
Law EH, Sherif B, Mostaghimi A, King B, Sinclair R, Mesinkovshka N, Hanson KA, Korver D, Chirila C. Patients with alopecia areata treated with ritlecitinib have improved patient-reported emotional symptoms and activity limitations due to hair loss: post hoc analyses of ALLEGRO-2b/3. Poster presented at the Maui Derm Hawaii 2024; January 22, 2024. Wailea, HI.
Abstact not available at this time.
Arends S, Choi JC, Becker B, Edwards T, Sreih A, Christodoulou A, Strand V. Qualitative study on patient-reported outcome measures in patients with Sjogren's disease. Poster presented at the American College of Rheumatology (ACR) Convergence 2024; November 17, 2024. Washington, DC. [abstract] Arthritis Rheumatol. 2024; 76(suppl 9).
Merola JF, Werth V, Choi JC, Becker B, Edwards T, Hobar C, Pomponi S, Strand V. Qualitative patient interview study in patients with systemic lupus erythematosus to assess patient perception of fatigue and skin-related symptoms. Poster presented at the American College of Rheumatology (ACR) Convergence 2024; November 17, 2024. Washington, DC. [abstract] Arthritis Rheumatol. 2024; 76(suppl 9).
Law E, Williams N, Korver D, Bender R, Mitra D, Schaefer G, Nelson LM. Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata. JEACP. 2024 Sep;3(4):1119-31. doi: 10.1002/jvc2.441
OBJECTIVES: To characterize the magnitudes of change in SALT scores corresponding to meaningful treatment benefits from the patient perspective.